8-K: Immunocore Holdings Amends Indenture for Convertible Senior Notes, Files Prospectus Supplement

Immunocore Holdings plc amended its indenture governing its 2.50% Convertible Senior Notes due 2030 and filed a prospectus supplement for the resale of up to $150 million of these notes and related American Depositary Shares (ADSs).

Summary

• Immunocore Holdings plc (the Company) and U.S. Bank Trust Company, National Association, as trustee, entered into the first supplemental indenture on March 17, 2025.
• This indenture supplements the original indenture dated February 2, 2024, which governs the Company's 2.50% Convertible Senior Notes due 2030.
• The supplemental indenture adds provisions relating to the Trust Indenture Act of 1939, as amended.
• On March 17, 2025, the Company also filed a prospectus supplement to its registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission.
• The prospectus supplement pertains to the resale by selling securityholders of up to $150,000,000 aggregate principal amount of the Notes and the American Depositary Shares (ADSs) issuable upon conversion of the Notes.
• Legal opinions from Cooley (UK) LLP and Cooley LLP regarding the legality of the securities being registered are also filed as exhibits.

Sentiment

Score: 6

Explanation: The document is a routine legal filing, so the sentiment is neutral. It reflects standard corporate actions related to existing financial instruments.

Positives

• The supplemental indenture ensures compliance with the Trust Indenture Act of 1939, which provides additional protection to noteholders.
• The filing of the prospectus supplement allows existing securityholders to resell their notes and ADSs, potentially increasing liquidity.

Future Outlook

The prospectus supplement allows for the potential resale of up to $150 million of notes and related ADSs by existing securityholders.

Industry Context

This announcement is typical for companies with convertible debt, as they often need to file prospectus supplements to allow for the resale of securities issued upon conversion of the debt.

Comparison to Industry Standards

• The terms of the convertible notes, such as the interest rate and maturity date, are within the typical range for similar offerings by biotechnology companies.
• The process of amending the indenture and filing a prospectus supplement is standard practice in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The resale of notes and ADSs could potentially dilute existing shareholders.
• Noteholders: The supplemental indenture provides additional protection to noteholders by ensuring compliance with the Trust Indenture Act.

Key Dates